Safety and Efficacy of Oral Deferasirox in Patients With Porphyria Cutanea Tarda
Recruitment status was: Recruiting
|Study Design:||Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
|Official Title:||A Phase II, Open Label Clinical Trial Exploring the Safety and the Efficacy of Oral Deferasirox in Patients Newly Diagnosed With Porphyria Cutanea Tarda (PCT) and Non-transfusion Iron Overload|
- The primary objective is to assess the safety of deferasirox in treating non-transfusion iron overload in patients with PCT. [ Time Frame: 6 months ]
- Related drug adverse events [ Time Frame: 6 months ]Incidence type and severity of drug related adverse events
- The change from baseline in serum ferritin after 12 and 24 weeks of treatment,The change from baseline in iron burden after 24 weeks of treatment measured by liver MRI T2,The evolution of clinical symptoms [ Time Frame: 6 months ]
- Chage from baseline in serum ferritin, iron burden, improvement in clincal symptoms, porphyrin levels [ Time Frame: 6 months ]
|Study Start Date:||January 2011|
|Estimated Study Completion Date:||December 2012|
|Estimated Primary Completion Date:||December 2012 (Final data collection date for primary outcome measure)|
Safety and efficacy
Orodispersible Tablet, 10 mg/Kg/day ± 5 mg/Kg/day during 24 weeks Deferasirox should be taken daily 30 minutes before breakfast
Other Name: DEFERASIROX
The primary objective is to assess the safety of deferasirox in treating non-transfusion iron overload in patients with PCT.
The secondary objective is to assess the effectiveness of deferasirox treatment :
After 3 and 6 months to:
•Lower serum ferritin from abnormal to normal standard ranges specified for males and females in this patient population.
After 6 months to :
•Lower liver iron content after 24 weeks of treatment measured by liver MRI T2
After 3 and 6 months to :
- Improve clinical symptoms, i.e. improvement in skin lesions (reduction or no new bullae formation), and skin fragility (photographs will be used).
- Reduce porphyrin levels.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01284946
|Contact: Benoit Coffin, Professorfirstname.lastname@example.org|
|Hopital Louis Mourier, GI unit,||Recruiting|
|Colombes, Ile de France, France, 92700|
|Contact: Benoit Coffin, Professor 33147606061 email@example.com|
|Principal Investigator: Deybach Jean-Charles, Professor|
|Principal Investigator:||Deybach Jean-Charles, Professor||Assistance Publique - Hôpitaux de Paris|